ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1131

Clinical Phenotypes of IgG4-related Disease in a Multi-ethnic Singapore Cohort

Choon Guan Chua1, Weida Chew1, Jeggrey Kay Wee Kam1, Hwee-Pin Phua1, Chengzi Chow1, Carol Yee-Leng Ng1, Wei-Yen Lim1, Ru Sin Lim1, Jereme Yijin Gan1, Mung-Ee Loh1, Tianrong Yeo2, David Zhiwei Law1, Stephrene Seok Wei Chan3, Amanda Francesca Ya-Fang Cheang4, Yong-Howe Ho1 and Charles Kien-Fong Vu1, 1Tan Tock Seng Hospital, Singapore, Singapore, 2National Neurology Institute, Singapore, Singapore, 3National University Hospital, Singapore, Singapore, 4Woodlands Health Campus, Singapore, Singapore

Meeting: ACR Convergence 2023

Keywords: American College of Rheumatology Criteria, classification criteria, Epidemiology, IgG4 Related Disease

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: (1124–1154) Miscellaneous Rheumatic & Inflammatory Diseases Poster II

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: IgG4-related disease (IgG4-RD) is an immune-mediated condition that is heterogenous and can result in organ failure. To understand the disease profile of our local population better, a multi-disciplinary team was formed to review the IgG4-RD patients seen in our hospital.

Methods: A chart review was undertaken for all IgG4-RD patients seen between 1 January 2015 and 30 September 2021 at a major tertiary hospital in Singapore. All patients included fulfilled the 2020 revised comprehensive diagnostic (RCD) criteria for IgG4-RD for at least possible IgG4-RD and then scored according to the 2019 ACR/EULAR classification.

Results: Of the 58 patients included in this study, 28 scored at least 20 (i.e. completely fulfilled) for the 2019 ACR/EULAR classification criteria. 45/58 (77.6%) were male, 43/58 (74.1%) were Chinese, and median age at onset of symptoms and at diagnosis were 60.4 [inter-quartile range (IQR) 49.4-66.1] and 61.5 (IQR 50.8-67.8) years respectively. 27/58 (46.6%) were smokers, 7/58 (12.1%) had cancers, and 40/58 (69.0%) had underlying metabolic co-morbidities. Patients who completely fulfilled the ACR/EULAR classification criteria scored between 21 and 44 (median 25.5), and those who did not fulfil had a score of 4 to 19 (median 10.5). The distribution of clinical phenotypes were: 22/58 (37.9%) head and neck, 20/58 (34.5%) pancreato-biliary, 12/58 (20.7%) Mikulicz/systemic, and 4/58 (6.9%) retro-peritoneal fibrosis/aortitis. The three commonest sites of involvement were pancreato-hepato-biliary 26/58 (44.8%), ocular 17/58 (29.3%) and lymph nodes 14/58 (24.1%). The median maximum serum IgG4 level and median IgG4/total IgG ratio were 220mg/dL (IQR 98-335) and 0.149 (IQR 0.078-0.236) respectively. Patients with Mikulicz/systemic phenotype had significantly higher median total serum IgG, IgG1, IgG2 and IgG3 (p< 0.050). The median maximum serum IgG4 level for those who fulfilled the ACR/EULAR criteria was 280.5mg/dL (IQR 160-816.5) and those who did not fulfil was 187.5mg/dL (87-235) (p=0.014). Histological samples were suggestive/conclusive of IgG4-RD in 68% of patients who completely fulfilled the ACR/EULAR classification criteria and 65.4% of patients who did not (p=0.843). Prednisolone was the commonest treatment prescribed to patients (49/58, 84.5%). Steroid-sparing immunosuppressants were given to 32/58 (55.2%), for which azathioprine was the commonest (25/58, 43.1%) followed by rituximab (7/58, 12.1%). Surgical excision was done in 23/58 (39.7%). 44/58 (75.9%) patients achieved disease remission after first presentation and 16/58 (27.6%) were in drug-free remission. Mortality was 4/58 (6.9%) with one case attributable to complications of IgG4-RD.

Conclusion: The head and neck IgG4-RD phenotype was the commonest one in our cohort, followed by pancreato-biliary. This condition occurred more commonly in males with no gender pre-dilection in any clinical phenotype. The ACR/EULAR classification criteria appeared too restrictive and the 2020 RCD was better able to capture the full spectral of IgG4-RD patients. The overall prognosis for IgG4-RD is good and histological investigation remains important for the diagnosis of this disease.

Supporting image 1

Description of patients

Supporting image 2

Distribution of IgG4-related disease phenotypes

Supporting image 3

Sites of IgG4-related disease manifestations


Disclosures: C. Chua: None; W. Chew: None; J. Kam: None; H. Phua: None; C. Chow: None; C. Ng: None; W. Lim: None; R. Lim: None; J. Gan: None; M. Loh: None; T. Yeo: None; D. Law: None; S. Chan: None; A. Cheang: None; Y. Ho: None; C. Vu: None.

To cite this abstract in AMA style:

Chua C, Chew W, Kam J, Phua H, Chow C, Ng C, Lim W, Lim R, Gan J, Loh M, Yeo T, Law D, Chan S, Cheang A, Ho Y, Vu C. Clinical Phenotypes of IgG4-related Disease in a Multi-ethnic Singapore Cohort [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/clinical-phenotypes-of-igg4-related-disease-in-a-multi-ethnic-singapore-cohort/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinical-phenotypes-of-igg4-related-disease-in-a-multi-ethnic-singapore-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology